Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

Pfizer Inc. (PFE) agreed to sell its remaining stake worth $3.3 billion in Haleon PLC (HLN), marking its exit from the UK-based consumer ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Pfizer closed at $25.60, slipping 0.43% in the latest session, outperforming broader market losses. While the S&P 500 dropped ...

The most recent trading session ended with Pfizer (PFE) standing at $25.60, reflecting a -0.43% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss ...

Low bond yields and interest rates are often credited with supporting higher prices in the stock market. That's because lower bond yields can make the potentially higher yields offered by stocks ...

These Chinese companies are also in a position to assign a lower price to these medicines compared to ... If you are looking ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

They forecast ... price growth and improve affordability. Annual gains were especially strong in the pricier Northeast and West regions, which Yun explains was the result of a record-high stock ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other undervalued US stocks. On a down day for major market averages, Paul Hickey, co-founder of Bespoke ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple ...

We like to invest in businesses with high returns, but the trend in a company’s ROIC is what often surprises the market and moves the stock price. Unfortunately, Pfizer’s ROIC has decreased over the ...